This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mazumdar, M. Articles by Bosl, G.J. Search for Related Content PubMed PubMed Citation Articles by Mazumdar, M. Articles by Bosl, G.J.

Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy

From the Department of Epidemiology and Biostatistics and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center; and Department of Medicine, Weill Medical College, Cornell University, New York, NY.

Address reprint requests to Madhu Mazumdar, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021; email: mazumdar{at}biost.mskcc.org

PURPOSE: The prognostic significance of the rate of decline of the serum tumor marker alpha-fetoprotein (AFP) and human chorionic gonadotrophin (HCG) during the first two cycles of chemotherapy in germ cell tumor (GCT) patients was initially reported by us, but its value has been debated. We re-examined this issue in the context of the International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification system and investigated the role of including in the analysis patients whose markers normalized early.

PATIENTS AND METHODS: One hundred eighty-nine GCT patients with elevated AFP/HCG marker values treated with platinum-based chemotherapy between 1986 and 1998 were included in this analysis. Patients were classified as good, intermediate, or poor risk by the IGCCCG criteria and as having satisfactory or unsatisfactory marker decline. Risk and marker decline were correlated with response, event-free survival, and overall survival.

RESULTS: Satisfactory marker decline predicted improved complete response (CR) proportion and event-free and overall survival (P < .0001). The CR proportion, 2-year event-free, and 2-year overall survival rates for patients with a satisfactory and unsatisfactory marker decline were 92% versus 62%, 91% versus 69%, and 95% versus 72%, respectively. Marker decline remained a significant variable for all three end points when adjusted for risk (P < .01) with the outcome differences most pronounced in the poor-risk group.

CONCLUSION: The rate of marker decline during chemotherapy has prognostic value independent of risk and may play a significant role in the management of poor-risk patients. It is appropriate to include patients whose markers normalized early.

Presented at the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999.

This article has been cited by other articles:

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				I. Shintaku, M. Satoh, E. Okajima, H. Fujimoto, T. Kamoto, O. Ogawa, K. Kawai, H. Akaza, T. Tsukamoto, S. Naito, et al. Survival of Metastatic Germ Cell Cancer Patients Assessed by International Germ Cell Consensus Classification in Japan Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 281 - 287. [Abstract] [Full Text] [PDF]

				K. Fizazi, J. Oldenburg, A. Dunant, I. Chen, R. Salvioni, J. T. Hartmann, M. De Santis, G. Daugaard, A. Flechon, U. de Giorgi, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study Ann. Onc., February 1, 2008; 19(2): 259 - 264. [Abstract] [Full Text] [PDF]

				D. J. Vaughn and E. A. Stadtmauer Poor-Prognosis Germ Cell Tumors: We Have Not Yet Crossed the Finish Line J. Clin. Oncol., January 20, 2007; 25(3): 239 - 240. [Full Text] [PDF]

				R. J. Motzer, C. J. Nichols, K. A. Margolin, J. Bacik, P. G. Richardson, N. J. Vogelzang, D. F. Bajorin, P. N. Lara Jr, L. Einhorn, M. Mazumdar, et al. Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors J. Clin. Oncol., January 20, 2007; 25(3): 247 - 256. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta and R. J. Motzer Chemotherapy for Advanced Germ Cell Tumors J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502. [Abstract] [Full Text] [PDF]

				K. Kawai, S. Hinotsu, T. Oikawa, N. Sekido, K. Hattori, N. Miyanaga, Y. Hasegawa, H. Kojima, T. Shimazui, and H. Akaza Treatment Outcome of Metastatic Testicular Cancer at a Single Institution in Japan, a Country with Low Incidence of Germ Cell Tumor Jpn. J. Clin. Oncol., November 1, 2006; 36(11): 723 - 730. [Abstract] [Full Text] [PDF]

				K. Fizazi, S. Culine, A. Kramar, R. J. Amato, J. Bouzy, I. Chen, J.-P. Droz, and C. J. Logothetis Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors J. Clin. Oncol., October 1, 2004; 22(19): 3868 - 3876. [Abstract] [Full Text] [PDF]

				G. C. Toner Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use J. Clin. Oncol., October 1, 2004; 22(19): 3842 - 3845. [Full Text] [PDF]

				M. R. van Dijk, E. W. Steyerberg, S. P. Stenning, and J. D. F. Habbema Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modelling: a validation study Ann. Onc., September 1, 2004; 15(9): 1400 - 1405. [Abstract] [Full Text] [PDF]

				S. Hatakeyama, C. Ohyama, S. Minagawa, T. Inoue, H. Kakinuma, A. Kyan, Y. Arai, T. Suga, J. Nakayama, T. Kato, et al. Functional Correlation of Trophinin Expression with the Malignancy of Testicular Germ Cell Tumor Cancer Res., June 15, 2004; 64(12): 4257 - 4262. [Abstract] [Full Text] [PDF]

				K. Fizazi, I. Chen, and C. J. Logothetis Germ-cell tumor survivors: the price for cure Ann. Onc., February 20, 2002; 13(2): 187 - 189. [Full Text] [PDF]